Skip to main content
Log in

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

European data on the polymorphic metabolism of debrisoquine, sparteine, dextromethorphan and mephenytoin have been collected.

No significant difference in phenotype frequencies was found between the separate series for debrisoquine, sparteine and dextromethorphan, which supports the claim that these probe drugs reflect the same enzyme polymorphism.

The mean frequency of the phenotype slow debrisoquine metaboliser was 7.65% based on 5005 determinations. The overall mean reflecting all three drugs and 8764 determinations was 7.40%. This is consistent with a gene frequency of 0.27 (95% confidence interval 0.26–0.28).

The overall mean of the phenotype slow metaboliser of mephenytoin was 3.52% corresponding to a gene frequency of 0.19 (confidence interval 0.17–0.20).

The incidence of slow metabolism of debrisoquine and possibly also of S-mephenytoin was homogeneous in the samples from European populations. This is of considerable interest as interethnic differences are now being found both in the phenotypic characters as well as the genotypes of polymorphic drug oxidation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Arvela P, Kirjarinta M, Kirjarinta M, Kärki N, Pelkonen O (1988) Polymorphism of debrisoquine hydroxylation among Finns and Lapps. Br J Clin Pharmacol 26: 601–603

    Google Scholar 

  • Bechtel P, Joanne C, Bechtel Y, Grandmottet M, Jounet JM (1986) Stabilité et/ou variabilité l'expression du polymorphisme génétique d'hydroxylation et d'acetylation chez de malades présentant des pathologies et soumis à des thérapeutiques variées. Ann Biol Clin 44: 361–367

    Google Scholar 

  • Benitez J, Llerena A, Cobaleda J (1988) Debrisoquin oxidation polymorphism in a Spanish population. Clin Pharmacol Ther 44: 74–77

    Google Scholar 

  • Bertilsson L (1989) Ethnic differences in drug disposition. In: Breimer DD, Crommelin DJA, Midha KK (eds) Topics in Pharmaceutical Sciences. 1989. Amsterdam, Medical Press

    Google Scholar 

  • Breimer DD, Schellens JHM, Soons PA (1988) Assessment of in vivo oxidative drug metabolizing enzyme activity in man by applying a cocktail approach. In: Miners J, Birkett DJ, Drew R, McManus M (eds) Proceedings of the VIIth International Symposium on Microsomes and Drug Oxidations (Adelaide, August 17–21, 1987) pp 232–240. Taylor and Francis, London

    Google Scholar 

  • Brøsen K, Gram LF (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36: 537–547

    Google Scholar 

  • Brøsen K, Otton SV, Gram LF (1985) Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 57: 357–360

    Google Scholar 

  • Drøhse A, Bathum L, Brøsen K, Gram LF (1989) Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol 27: 620–625

    Google Scholar 

  • Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C (1986) The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 22: 49–53

    Google Scholar 

  • Eichelbaum M, Spannbrucker N, Dengler HJ (1975) N-Oxidation of sparteine in man and its interindividual differences. Naunyn Schmiedebergs Arch Pharmacol 287 (Suppl): R94 (Proceedings)

  • Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187

    Google Scholar 

  • Emery AEH (1986) Methodology in Medical Genetics. Churchill Livingstone, p 5

  • Evans DAP, Manley KA, McKusick VA (1960) Genetic control of isoniazid metabolism in man. Br Med J 2: 485–491

    Google Scholar 

  • Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105

    Google Scholar 

  • Gachályi B, Róna K, Vas A, Káldor A (1986) A debrisoquin hydroxiláció polimorfizmusának vizsgálata. Orvosi Hetilap 127: 2299–2301

    Google Scholar 

  • Harris H, Hopkinson DA, Luffman J (1968) Enzyme diversity in human populations. Ann NY Acad Sci 151: 232–242

    Google Scholar 

  • Inaba T, Vinks A, Otton SV, Kalow W (1983) Comparative pharmacogenetics of sparteine and debrisoquine. Clin Pharmacol Ther 33: 394–399

    Google Scholar 

  • Iyun AO, Lennard MS, Tucker GT, Woods HF (1986) Metoprolol and debrisoquin metabolism in Nigerians: Lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 40: 387–394

    Google Scholar 

  • Jackson PR, Tucker GT, Lennard MS, Woods HF (1986) Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol 22: 541–550

    Google Scholar 

  • Jacqz E, Dulac H, Mathieu H (1988) Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 35: 167–171

    Google Scholar 

  • Küpfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: 753–759

    Google Scholar 

  • Larrey D, Amouyal G, Tinel M, Letteron P, Berson A, Labbe G, Pessayre D (1987) Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol 24: 676–679

    Google Scholar 

  • Leclercq V, Desager JP, van Nieuwenhuyze Y, Harvengt C (1987) Prevalence of drug hydroxylator phenotypes in Belgium. Eur J Clin Pharmacol 33: 439–440

    Google Scholar 

  • Leopold G (1986) Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol 8 [Suppl 11]: 16–20

    Google Scholar 

  • Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet II: 584–586

    Google Scholar 

  • McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF (1985) Metoprolol metabolism and debrisoquine oxidation polymorphism — population and family studies. Br J Clin Pharmacol 20: 555–566

    Google Scholar 

  • Paar WD, Schuhler H, Fimmers R, Dengler HJ (1989) Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma. Eur J Clin Pharmacol 36: 555–560

    Google Scholar 

  • Sanz EJ, Villén T, Alm C, Bertilsson L (1989) S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 45: 495–499

    Google Scholar 

  • Schellens JHM, Danhof M, Breimer DD (1986) The poor metabolizer incidence of sparteine, mephenytoin and nifedipine in a Dutch population. Acta Pharmacol Toxicol 59 [Suppl V]: 252

    Google Scholar 

  • Schmid B, Bircher J, Preisig R, Küpfer A (1985) Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38: 618–624

    Google Scholar 

  • Skoda RC, Gonzalez FJ, Demierre A, Meyer UA (1988) Two mutant alleles of the human cytochrome P-450dbl gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci 85: 5240–5243

    Google Scholar 

  • Steiner E, Alván G, Garle M, Maguire JH, Lind M, Nilson SO, Tomson T, McClanahan JS, SjÖqvist F (1987) The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin. Clin Pharmacol Ther 42: 326–333

    Google Scholar 

  • Steiner E, Bertilsson L, Säwe J, Bertling I, Sjöqvist F (1988) Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44: 431–435

    Google Scholar 

  • Steiner E, Iselius L, Alván G, Lindsten J, Sjöqvist F (1985) A family study of genetic and environmental factors influencing polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 38: 394–492

    Google Scholar 

  • Syvälahti EKG, Lindberg R, Kallio J, de Vocht M (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 22: 89–92

    Google Scholar 

  • Szórády I, Sánta A (1987) Drug hydroxylator phenotype in Hungary. Eur J Clin Pharmacol 32: 325

    Google Scholar 

  • Vogel F, Motulsky AG (eds) (1986) Human Genetics. Springer, Berlin, Heidelberg, New York

    Google Scholar 

  • Woolhouse NM, Eichelbaum M, Oates NS, Idle JR, Smith RL (1985) Dissociation of coregulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 37: 374–378

    Google Scholar 

  • Yue QY, Bertilsson L, Dahl-Puustinen ML, Säwe J, Sjöqvist F, Johansson I, Ingelman-Sundberg M (1989) Dissassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet II: 870

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alván, G., Bechtel, P., Iselius, L. et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39, 533–537 (1990). https://doi.org/10.1007/BF00316090

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00316090

Key words

Navigation